In our study, 28.8% of ERA patients met the indication for anti-TNF, and HLA-B27 positive individuals were significantly more likely to be prescribed it compared to HLA-B27 negative groups. The gene discussed is TNF; the disease is enthesitis-related juvenile idiopathic arthritis.